Safe, effective one-year outcomes in severe tricuspid regurgitation, enhancing symptoms and reducing admissions.

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.

HEART failure with preserved ejection fraction (HFpEF) is present in 74% of patients with severe isolated secondary tricuspid ...

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England ...

severe tricuspid regurgitation (TR). For the hierarchical primary outcome, the win ratio favored TTVR using the Evoque device (Edwards Lifesciences; 2.02; 95% CI 1.56-2.62), with investigators ...

W EDNESDAY, Nov. 6, 2024 (HealthDay News) -- For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid ...

Rebecca T. Hahn, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues randomly assigned 400 patients with severe symptomatic tricuspid regurgitation to undergo ...

Among study participants with symptomatic, severe tricuspid regurgitation (TR), those randomized to TTVR, in lieu of medical therapy alone, had significantly better 1-year outcomes per win ratio ...

A Charleston woman was always short of breath and suffered from an undertreated heart problem. A new device at MUSC has her ...

Patients enrolled in the TRISCEND II trial had at least severe tricuspid regurgitation (TR). The EVOQUE valve was successfully implanted in 95.4 percent of patients, and of those who received the ...